Yu Peng, Li Jingyang, Luo Yanqing, Sun Jiayi, Hu Yingfan, Lin Bo, Meng Xianli, Xiang Li
State Key Laboratory of Southwestern, Chinese Medicine Resources, College of Pharmacy, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R. China.
School of Preclinical Medicine, Chengdu University, Chengdu 610106, P. R. China.
Am J Chin Med. 2023;51(2):279-308. doi: 10.1142/S0192415X23500155. Epub 2023 Jan 18.
Breast cancer is one of the most common malignancies in women, and exhibits high metastasis, recurrence and fatality rates. Novel therapies for breast cancer are constantly emerging, such as targeted therapy, oncolytic virotherapy, and immunotherapy. Despite their potential, these new therapies are still in their infancy, and chemotherapy remains the standard treatment for breast cancer. Therefore, it is of great significance to develop safe and efficient treatment drugs or adjuvants for breast cancer treatment. Traditional Chinese medicine (TCM) has a long clinical history in China, in which Georgi exhibits favorable antibreast cancer activities. We therefore conducted a systematic review of the available literature to better understand the molecular mechanisms of in breast cancer treatment. and its active components (baicalein, baicalin, wogonin, wogonoside, oroxylin A and scutellarin) exhibited promising antibreast cancer activity through proliferation inhibition, apoptosis induction, invasion and metastasis blockading, and drug-resistance and non-coding RNA regulation. Additionally, senescence, autophagy, angiogenesis, and glycolysis mechanisms were observed to play a role in their antibreast cancer activity. Furthermore, multiple signaling pathways contributed to the antitumor effects of , such as the NF-[Formula: see text]B, Wnt/[Formula: see text]-catenin, SATB1, Bcl2 family proteins, Caspase, PI3K/Akt, mTOR, ERK, p38-MAPK, TGF-[Formula: see text]/Smad, and Hippo/YAP pathways. This review provides valuable insights into the role of as a breast cancer treatment and acts as a foundation for further investigations in this field.
乳腺癌是女性最常见的恶性肿瘤之一，具有高转移率、高复发率和高死亡率。乳腺癌的新型治疗方法不断涌现，如靶向治疗、溶瘤病毒疗法和免疫疗法。尽管这些新疗法具有潜力，但仍处于起步阶段，化疗仍是乳腺癌的标准治疗方法。因此，开发安全有效的乳腺癌治疗药物或佐剂具有重要意义。中药在中国有着悠久的临床历史，其中黄芩表现出良好的抗乳腺癌活性。因此，我们对现有文献进行了系统综述，以更好地了解黄芩在乳腺癌治疗中的分子机制。黄芩及其活性成分（黄芩素、黄芩苷、汉黄芩素、汉黄芩苷、木犀草素和野黄芩苷）通过抑制增殖、诱导凋亡、阻断侵袭和转移以及调节耐药性和非编码RNA，展现出有前景的抗乳腺癌活性。此外，衰老、自噬、血管生成和糖酵解机制在其抗乳腺癌活性中也发挥作用。此外，多种信号通路促成了黄芩的抗肿瘤作用，如NF-κB、Wnt/β-连环蛋白、SATB1、Bcl2家族蛋白、半胱天冬酶、PI3K/Akt、mTOR、ERK、p38-MAPK、TGF-β/Smad和Hippo/YAP信号通路。本综述为黄芩作为乳腺癌治疗药物的作用提供了有价值的见解，并为该领域的进一步研究奠定了基础。
